Watson Pharmaceuticals announced that the company transferred the license to Yuanda Pharmaceutical Co., Ltd. to sell buspirone hydrochloride tablets in China to hold all rights, including drug registration certificates, patents and technical data. Recently, the State Drug Administration approved the change of the marketing license holder for this drug from Watson Pharmaceuticals to Yuanda Pharmaceuticals. All the procedures for changing the drug registration certificate involved in this transaction have been completed. The company has received part of the transfer payment, and the remaining amount will be collected one after another according to the payment schedule and conditions agreed in the agreement. The transaction will not have a significant impact on the company's operating performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.